{"filing":{"accession_number":"0001193125-26-403429","cik":"0001434316","ticker":"FATE","company_name":"FATE THERAPEUTICS INC","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-25","primary_document":"fate-20260925.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526403429/fate-20260925.htm"},"events":[{"id":35324,"run_id":32532,"accession_number":"0001193125-26-403429","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Fate Therapeutics received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the Phase 2 RECLAIM-LN clinical trial of FT819. This is a material operational and strategic event—a significant external funding award that advances the company's clinical development program for a potentially registrational trial in lupus nephritis. While not a traditional earnings release, M\u0026A activity, or governance matter, this grant materially supports the company's pipeline advancement and is disclosed as a press release in Item 8.01 (Other Events), making it an operational milestone rather than a routine administrative disclosure.","company_name":"FATE THERAPEUTICS INC","ticker":"FATE","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39338,"accession_number":"0001193125-26-403429","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Fate Therapeutics received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the Phase 2 RECLAIM-LN clinical trial of FT819. This is a material operational and strategic event—a significant external funding award that advances the company's clinical development program for a potentially registrational trial in lupus nephritis. While not a traditional earnings release, M\u0026A activity, or governance matter, this grant materially supports the company's pipeline advancement and is disclosed as a press release in Item 8.01 (Other Events), making it an operational milestone rather than a routine administrative disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:12:03.881531+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39338,"accession_number":"0001193125-26-403429","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Fate Therapeutics received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the Phase 2 RECLAIM-LN clinical trial of FT819. This is a material operational and strategic event—a significant external funding award that advances the company's clinical development program for a potentially registrational trial in lupus nephritis. While not a traditional earnings release, M\u0026A activity, or governance matter, this grant materially supports the company's pipeline advancement and is disclosed as a press release in Item 8.01 (Other Events), making it an operational milestone rather than a routine administrative disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:12:03.881531+00:00","company_name":"FATE THERAPEUTICS INC","ticker":"FATE","filing_date":"2026-09-28"}]}